Dermal inflammation in psoriatic arthritis, the association to molecular mass of hyaluronan and effect of adalimumab. A prospective, open-label, multi-center study of hyaluronan molecular mass distribution in psoriatic arthritis patients compared to healthy subjects.
Phase of Trial: Phase IV
Latest Information Update: 17 Aug 2013
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriatic arthritis
- Focus Biomarker; Pharmacodynamics
- 17 Aug 2013 New trial record